

YOUR HEP-C PATIENT DIDN'T RESPOND. WHAT'S NEXT?



REWIND



PAUSE



INFERGEN

Only Infergen® offers a proven treatment option for the significant and growing number of nonresponders and relapsers.^{1,2}

You don't have to rewind and retreat with another interferon alfa-2 or watch and wait for a new therapy. It's your move. Move forward with the unique interferon—bioengineered Infergen.

Infergen is indicated for the treatment of chronic HCV infection in patients 18 years of age or older with compensated liver disease. Other causes of hepatitis, such as viral hepatitis B or autoimmune hepatitis, should be ruled out prior to initiation of therapy with Infergen.

The most commonly reported adverse events during initial and subsequent treatment were flulike symptoms (eg, headache, fatigue, fever, myalgia, and rigors).

Alpha interferons, including Interferon alfacon-1, cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Patients with persistently severe or worsening symptoms of these conditions should be withdrawn from therapy. In many but not all cases, these disorders resolve after stopping Interferon alfacon-1 therapy. See WARNINGS and ADVERSE REACTIONS in full prescribing information.

Please see brief summary of prescribing information and references on following page.

The Consensus Interferon
INFERGEN[™]
Interferon alfacon-1

A First Choice for a Second Chance

For more information visit www.infergen.com

